Jonathan D. Bargh

Jonathan D. Bargh

Auto-generated profile, based on publicly available information

Jonathan D. Bargh

Department of Chemistry, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
JBJonathan D. Bargh
Jonathan D. Bargh
AIAlbert Isidro-Llobet
Albert Isidro-Llobet
JPJeremy S. Parker
Jeremy S. Parker
DSDavid Spring
David Spring
This tutorial review summarises the advances in the field of cleavable linker technologies for antibody–drug conjugates (ADCs).

8 December 2020 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
SWStephen J. Walsh
Stephen J. Walsh
JBJonathan D. Bargh
Jonathan D. Bargh
FDFriederike M. Dannheim
Friederike M. Dannheim
AHAbigail R. Hanby
Abigail R. Hanby
HSHikaru Seki
Hikaru Seki
DSDavid Spring
David Spring
Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. This review summarises the advances made in the construction of homogenous ADCs.

2 November 2022 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
NANicola Ashman
Nicola Ashman
JBJonathan D. Bargh
Jonathan D. Bargh
DSDavid Spring
David Spring
This review introduces non-internalising Antibody–Drug Conjugates (ADCs), highlighting the linker chemistry that enables extracellular payload release.

27 January 2020 in Chemical Science
Verified
Journal Article
Open access
PDF file
JBJonathan D. Bargh
Jonathan D. Bargh
SWStephen J. Walsh
Stephen J. Walsh
AIAlbert Isidro-Llobet
Albert Isidro-Llobet
SOSoleilmane Omarjee
Soleilmane Omarjee
JCJason S. Carroll
Jason S. Carroll
DSDavid Spring
David Spring
Antibody-drug conjugates (ADCs) are a class of targeted drug delivery agents combining the cell-selectivity of monoclonal antibodies (mAbs) and the cytotoxicity of small molecules. These two components are joined by a covalent linker, whose nature is critical to the efficacy and safety of the ADC. Enzyme-cleavable dipeptidic linkers have emerged as a particularly effective ADC linker type due to their ability to selectively release the payload in the lysosomes of target cells. However, these linkers have a number of drawbacks, including instability in rodent plasma and their inherently high hydrophobicity. Here we show that arylsulfate-containing ADC linkers are cleaved by lysosomal sulfatase enzymes to tracelessly release their payload, while circumventing the instability problems associated with dipeptide-linkers. When incorporated with trastuzumab and the highly potent monomethyl auristatin E (MMAE) payload, the arylsulfate-containing ADC 2 and ADC 3 were more cytotoxic than the non-cleavable ADC 4 against HER2-positive cells, while maintaining selectivity over HER2-negative cells. We propose that the stability, solubility and synthetic tractability of our arylsulfate linkers make them an attractive new motif for cleavable ADC linkers, with clear benefits over the widely used dipeptidic linkers.

7 June 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
HSHikaru Seki
Hikaru Seki
SWStephen J. Walsh
Stephen J. Walsh
JBJonathan D. Bargh
Jonathan D. Bargh
JPJeremy S. Parker
Jeremy S. Parker
JCJason Carroll
Jason Carroll
DSDavid Spring
David Spring
Vinylheteroarene linkers can chemoselectively modify cysteine residues in proteins and antibodies. These linkers give stable bioconjugates, and were used to synthesise efficacious antibody-drug conjugates.

2 March 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
JBJonathan D. Bargh
Jonathan D. Bargh
SWStephen J. Walsh
Stephen J. Walsh
NANicola Ashman
Nicola Ashman
AIAlbert Isidro-Llobet
Albert Isidro-Llobet
JCJason S. Carroll
Jason S. Carroll
DSDavid Spring
David Spring
A novel enzyme cleavable linker for antibody–drug conjugates is reported. The 3-O-sulfo-β-galactose linker is cleaved sequentially by two lysosomal enzymes – arylsulfatase A and β-galactosidase – to release the payload in targeted cells. An α-HER2 antibody–drug conjugate synthesised using this highly hydrophilic dual-cleavable linker exhibited excellent cytotoxicity and selectivity.